DOCSLIB.ORG

Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco Address Originator Bristol-Myers Squibb Co University of Milan . Istituto di Chimica Farmaceutica e Tossicologica Viale Abruzzi 42 Licensee Merck & Co Inc 20131 Milano . Italy Status Pre-registration Email: [email protected] . Indications Metabolic disorder, Non-insulin-dependent Current Opinion in Investigational Drugs 2005 6(4): diabetes © The Thomson Corporation ISSN 1472-4472 . Actions Antihyperlipidemic agent, Hypoglycemic agent, Bristol-Myers Squibb and Merck & Co are co-developing Insulin sensitizer, PPARα agonist, PPARγ agonist muraglitazar, a dual peroxisome proliferator-activated receptor-α/γ . agonist, for the potential treatment of type 2 diabetes and other Synonym BMS-298585 metabolic disorders. In November 2004, approval was anticipated as early as mid-2005. Registry No: 331741-94-7 Introduction [579218], [579221], [579457], [579459]. PPARγ is expressed in Type 2 diabetes is a complex metabolic disorder that is adipose tissue, lower intestine and cells involved in characterized by hyperglycemia, insulin resistance and immunity. Activation of PPARγ regulates glucose and lipid defects in insulin secretion. The disease is associated with homeostasis, and triggers insulin sensitization [579216], older age, obesity, a family history of diabetes and physical [579218], [579458], [579461]. PPARδ is expressed inactivity. The prevalence of type 2 diabetes is increasing ubiquitously and has been found to be effective in rapidly, and the World Health Organization warns that, controlling dyslipidemia and cardiovascular diseases unless appropriate action is taken, the number of sufferers [579216]. PPARα agonists are used as potent hypolipidemic will double to over 350 million individuals by the year compounds, increasing plasma high-density lipoprotein 2030. Worryingly, it is estimated that only half of sufferers (HDL)-cholesterol and reducing free fatty acids, are diagnosed with the condition [www.who.int]. Therefore, triglycerides, low-density lipoprotein (LDL)-cholesterol and prevention and treatment of type 2 diabetes mellitus the number of small dense LDL particles. The use of PPARγ represents a major clinical challenge. Although the activators in the treatment of type 2 diabetes is well pathophysiology of type 2 diabetes is not completely established. However, several unwanted effects are understood, over the past decade our understanding of fat associated to both treatments. In particular, weight gain, and sugar metabolism has greatly improved, and evidence edema, mild anemia and possible increased risk of suggests that, besides altered glucose metabolism, congestive heart failure often accompanies abnormalities in fat metabolism also play a central role in γ , α the pathogenesis of this disease [579204], [579206], PPAR stimulation while activation of PPAR results in 579221 [579210]. increased lipolysis and oxidation of fatty acids [ ], 579463 579464 579465 [ ], [ ], [ ]. The peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor Given the importance of simultaneously controlling glucose superfamily. Three receptor isoforms have been cloned, homeostasis, insulin sensitization and lipid metabolism in α γ namely PPARα, -γ and -β/δ. Each subtype is expressed in a type 2 diabetes, activation of both PPAR and subtypes tissue-specific manner, and activity is exerted via binding to should be beneficial. This goal was initially attempted by a specific consensus DNA sequences, the peroxisome combination of two selective agonists [579206], [579216], α γ proliferator response elements (PPREs). PPARs are major [579466], [587224], but a number of PPAR / dual agonists regulators of lipid and glucose metabolism, and have been have also recently appeared in the literature; KRP-297, implicated in the regulation of insulin sensitivity and tesaglitazar (AstraZeneca plc), DRF-4158 (Dr Reddys symptoms of obesity, as well as in the control of food intake. Research Foundation), ragaglitazar, GW-409544, LY-465608 Thus, they have emerged as potential molecular targets for (Eli Lilly & Co) and LY-510929 (Eli Lilly & Co/Ligand the treatment of human metabolic disorders. In particular, Pharmaceuticals Inc [579204]. This evaluation focuses on α γ PPARα (present in the liver, heart and, to a lesser extent, muraglitazar (BMS-298585), a PPAR / dual agonist that is skeletal muscle) plays a significant role in the regulation of being developed by Bristol-Myers Squibb Co (BMS) in nutrient metabolism, including fatty acid oxidation, collaboration with Merck & Co Inc, for the oral treatment of gluconeogenesis and amino acid metabolism. The type 2 diabetes [454850], [535305], [535435]. modulation of PPARα function could be important for the regulation of compensatory insulin secretion, which is Synthesis and SAR suggested to be involved both in glucoregulation and Muraglitazar is a non-thiazolidinedione, oxybenzylglycine liporegulation. Deregulation of PPARα contributes to the PPARα/γ dual agonist. The synthesis of muraglitazar and pathogenesis of a variety of disease states, such as cardiac other analogs is detailed in WO-00121602, which describes hypertrophy and hyperlipidemia [579213], [579216], 30 reaction schemes. In one example of the synthetic route, muraglitazar was synthesized by reacting In addition, studies with different models demonstrated that 4-hydroxybenzaldehyde and 5-methyl-2-phenyloxazole-4- muraglitazar was able to normalize lipid content in the liver. ethanol in triphenylphosphine and diethylazodicarboxylate This was because PPARα activation enhanced lipid to yield the corresponding benzaldehyde intermediate, metabolism and lead to lipid lowering, which complements which was in turn reacted with 4-methoxy-N-benzylglycine the insulin sensitizing antidiabetic effects of PPARγ ethyl ester and sodium triacetoxyborohydride. The ester activation [454180], [454181]. group was removed by hydrolysis with sodium hydroxide to yield muraglitazar. A subsequent study was conducted in severely diabetic db/db mice administered muraglitazar and the selective Preclinical Development PPARγ agonist rosiglitazone (both at 10 mg/kg/day) for Binding studies with muraglitazar, based on a fluorescence 2 weeks. Fasting glucose was decreased by 51 and 30%, polarization assay, demonstrated IC50 values of 0.42 and 0.14 respectively. After an oral glucose challenge, the area under µM for PPARα and PPARγ, respectively. Muraglitazar did the glucose-response curve was decreased by 30 and 20%, not, however, show any significant activity towards PPARδ, respectively [541486]. In a parallel experiment on db/db mice or on a wide series of other nuclear hormone receptors [541486], muraglitazar (0.1 to 30 mg/kg/day for 4 weeks) [454098]. Potent agonistic activity at both PPARα and induced a progressive, dose-dependent lowering of plasma triglycerides, free fatty acids, glucose and insulin. It should PPARγ was demonstrated in transiently transfected Hep-G2 also be noted that treatment with muraglitazar (3 and CV-1 cell lines, respectively, where the respective EC 50 mg/kg/day) for 4 weeks normalized the level of plasma values of muraglitazar were 0.24 and 0.12 µM [454098], adiponectin, which was very low in db/db mice with respect [454181], [463529]. µ to normal C57BL/6 mice (3.9 versus 20 g/ml). In addition, the compound was able to decrease corticosterone levels in a Muraglitazar was tested in hamsters fed a high-fat diet dose-dependent manner. Finally, a reduction in urine output [454181], [463529]. This represents a highly predictive from 12 to 1.9 ml was obtained after administration of 30 animal model for the treatment of human hyperlipidemia. In mg/kg/day of muraglitazar. fact, unlike mice, these animals carry cholesterol in both HDL and LDL fractions, as do humans. Oral administration A study was conducted to verify whether muraglitazar was α of muraglitazar led to in vivo PPAR activation, as able to act directly upon macrophage foam cells, thereby confirmed by the induction of the acyl CoA oxidase gene retarding atherogenesis [542286]. Differentiating THP1 and suppression of the apoCIII gene in liver. This is in macrophage cells were treated for 24 h with 10 µM of either γ contrast to treatment with the PPAR agonist rosaglitazone, muraglitazar or rosiglitazone in vitro. The results indicated which did not cause induction of the acyl CoA oxidase gene. that 10 µM of muraglitazar induced the expression of In vivo, PPARγ activation was confirmed by the induction of multiple genes involved in reverse cholesterol transport, lipoprotein lipase and aP2 genes in white adipose tissue. namely CD36 (3.8-fold), apoE (5.9-fold), liver X receptor Administration of muraglitazar (10 mg/kg/day) for 4 weeks (LXR)α/β (3.8-fold), and ATP-binding cassette transporter 1 produced normalization of fasting plasma triglyceride (ABCA1) (2.8-fold). At the same concentration, rosiglitazone (-81%), very low-density lipoprotein (VLDL)+LDL- only weakly induced expression of CD36 (2.3-fold) and apoE cholesterol (-38%), free fatty acids (-60%) and fasting plasma (2.0-fold), and was not able to increase either LXRα/β or glucose (-19%) levels. At a dose of 30 mg/kg/day, fasting ABCA1 mRNA levels. When compared for their functional plasma glucose was lowered by 41%. In addition, activities, muraglitazar increased cholesterol efflux from administration of muraglitazar (10 mg/kg/day) for 6 weeks THP1 cells by 78%, while rosiglitazone increased it by only in fed animals caused triglyceride
Load more

Recommended publications
  • Rosiglitazone-Associated Fractures in Type 2 Diabetes an Analysis from a Diabetes Outcome Progression Trial (ADOPT)
    Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Rosiglitazone-Associated Fractures in Type 2 Diabetes An analysis from A Diabetes Outcome Progression Trial (ADOPT) 1 7 STEVEN E. KAHN, MB, CHB DAHONG YU, PHD preclinical data and better understand the 2 7 BERNARD ZINMAN, MD MARK A. HEISE, PHD clinical implications of and possible interven- 3 7 JOHN M. LACHIN, SCD R. PAUL AFTRING, MD, PHD tions for these findings. 4 8 STEVEN M. HAFFNER, MD GIANCARLO VIBERTI, MD 5 WILLIAM H. HERMAN, MD FOR THE ADIABETES OUTCOME Diabetes Care 31:845–851, 2008 6 RURY R. HOLMAN, MD PROGRESSION TRIAL (ADOPT) STUDY 7 BARBARA G. KRAVITZ, MS GROUP* ype 2 diabetes is associated with an increased risk of fractures, with the risk increasing with longer duration OBJECTIVE — The purpose of this study was to examine possible factors associated with the T increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial of disease (1,2). These fractures affect pre- (ADOPT). dominantly the hip, arm, and foot (1–5) and occur despite the fact that bone min- RESEARCH DESIGN AND METHODS — Data from the 1,840 women and 2,511 men eral density is either normal or even in- randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years creased in patients with type 2 diabetes were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. compared with those who are not hyper- glycemic (5–7). Although the reason for RESULTS — In men, fracture rates did not differ between treatment groups.
    [Show full text]
  • The Antidiabetic Drug Lobeglitazone Has the Potential to Inhibit PTP1B T Activity ⁎ Ruth F
    Bioorganic Chemistry 100 (2020) 103927 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B T activity ⁎ Ruth F. Rochaa, Tiago Rodriguesc, Angela C.O. Menegattia,b, , Gonçalo J.L. Bernardesc,d, Hernán Terenzia a Centro de Biologia Molecular Estrutural, Departamento de Bioquímica, Universidade Federal de Santa Catarina, Campus Trindade, 88040-900 Florianópolis, SC, Brazil b Universidade Federal do Piauí, CPCE, 64900-000 Bom Jesus, PI, Brazil c Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal d Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK ARTICLE INFO ABSTRACT Keywords: Protein tyrosine phosphatase 1B (PTP1B) is considered a potential therapeutic target for the treatment of type 2 Thiazolidinediones diabetes mellitus (T2DM), since this enzyme plays a significant role to down-regulate insulin and leptin sig- Lobeglitazone nalling and its over expression has been implicated in the development of insulin resistance, T2DM and obesity. PPAR-γ Some thiazolidinediones (TZD) derivatives have been reported as promising PTP1B inhibitors with anti hy- PTP1B perglycemic effects. Recently, lobeglitazone, a new TZD, was described as an antidiabetic drug that targetsthe Non-competitive inhibitors PPAR-γ (peroxisome γ proliferator-activated receptor) pathway, but no information on its effects on PTP1B have been reported to date. We investigated the effects of lobeglitazone on PTP1B activity in vitro. Surprisingly, lobeglitazone led to moderate inhibition on PTP1B (IC50 42.8 ± 3.8 µM) activity and to a non-competitive reversible mechanism of action.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba
    Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba by Kim¡ T. G. Guilbert A Thesis submitted to The Faculty of Graduate Studies in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE Faculty of Pharmacy The University of Manitoba Winnipeg, Manitoba @ Kimi T.G. Guilbert, March 2005 TIIE UMYERSITY OF MANITOBA F'ACULTY OF GRADUATE STTJDIES +g+ù+ COPYRIGIIT PERMISSION PAGE Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba BY Kimi T.G. Guilbert A ThesisÆracticum submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfillment of the requirements of the degree of MASTER OF SCIENCE KIMI T.G. GTIILBERT O2()O5 Permission has been granted to the Library of The University of Manitoba to lend or sell copies of this thesis/practicum, to the National Library of Canada to microfïlm this thesis and to lend or sell copies of the film, and to University Microfilm Inc. to publish an abstract of this thesis/practicum. The author reserves other publication rights, and neither this thesis/practicum nor extensive extracts from it may be printed or otherwise reproduced without the author's written permission. Acknowledgements Upon initiation of this project I had a clear objective in mind--to learn more. As with many endeavors in life that are worthwhile, the path I have followed has brought me many places I did not anticipate at the beginning of my journey. ln reaching the end, it is without a doubt that I did learn more, and the knowledge I have been able to take with me includes a wider spectrum than the topic of population health and medication utilization.
    [Show full text]
  • Identification of a Novel Selective Agonist of Pparc with No Promotion
    OPEN Identification of a novel selective agonist c SUBJECT AREAS: of PPAR with no promotion of DRUG DISCOVERY ENDOCRINE SYSTEM AND adipogenesis and less inhibition of METABOLIC DISEASES osteoblastogenesis Received 28 October 2014 Chang Liu, Tingting Feng, Ningyu Zhu, Peng Liu, Xiaowan Han, Minghua Chen, Xiao Wang, Ni Li, Yongzhen Li, Yanni Xu & Shuyi Si Accepted 5 March 2015 Published Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China. 1 April 2015 Nuclear receptor peroxisome proliferator-activated receptor c (PPARc) plays an important role in the regulation of glucose homeostasis and lipid metabolism. However, current PPARc-targeting drugs such as Correspondence and thiazolidinediones (TZDs) are associated with undesirable side effects. We identified a small molecular requests for materials compound, F12016, as a selective PPARc agonist by virtual screening, which showed moderate PPARc should be addressed to agonistic activity and binding ability for PPARc. F12016 did not activate other PPAR subtypes at 30 mM and S.S. (sisyimb@hotmail. selectively modulated PPARc target gene expression. In diabetic KKAy mice, F12016 had insulin-sensitizing com) or Y.X. and glucose-lowering properties, and suppressed weight gain. In vitro, F12016 effectively increased glucose c (xuyanniwendeng@ uptake and blocked cyclin-dependent kinase 5-mediated phosphorylation of PPAR at Ser273, but slightly triggered adipogenesis and less inhibited osteoblastogenesis than rosiglitazone. Moreover, compared with hotmail.com) the full agonist rosiglitazone, F12016 had a distinct group of coregulators and a different predicted binding mode for the PPARc ligand-binding domain. A site mutation assay confirmed the key epitopes, especially Tyr473 in AF-2.
    [Show full text]
  • Diabetes Mellitus Typ 2 Medikamentöse Therapie
    Übersicht AMT Diabetes mellitus Typ 2 Medikamentöse Therapie L. Cornelius Bollheimer, Christiane Girlich, Ulrike Woenckhaus und Roland Büttner, Regensburg Arzneimitteltherapie 2007;25:175–86. Literatur NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16: 621–9. 1. Deutsche Diabetes Gesellschaft. Evidenzbasierte Leitlinie: Epidemiologie 24. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein und Verlauf des Diabetes mellitus in Deutschland. http://www.deutsche- level in well-controlled type 2 diabetics with metabolic syndrome. En- diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Update_ docrine 2003;20:215–8. Epidemiologie_05_2004_neues_Layout.pdf. Internetdokument. 2004. 25. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 dia- 2. Seufert J. Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2- betes mellitus. Drugs 2005;65:385–411. Diabetes-mellitus. Dtsch Ärzteblatt 2006;103:A934–42. 26. Parhofer KG, Laubach E, Geiss HC, Otto C. Effect of glucose control on 3. Deutsche Diabetes Gesellschaft. Praxis-Leitlinien der Deutschen Diabe- lipid levels in patients with type 2 diabetes. Dtsch Med Wochenschr tes Gesellschaft. Diabetologie und Stoffwechsel 2006;1:S2. 2002;127:958–62. 4. Häring HU, Matthaei S. Behandlung des Diabetes mellitus Typ 2. Diabe- 27. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin ac- tologie und Stoffwechsel 2006;1:S205–10. tion in obese and lean noninsulin-dependent diabetic subjects. J Clin 5. Brueckel J, Kerner W. Definition, Klassifikation und Diagnostik des Dia- Endocrinol Metab 1991;73:1294–301. betes mellitus. Diabetologie und Stoffwechsel 2006;1:S177–80. 28. Cryer DR, Nicholas SP, Henry DH, Mills DJ, et al. Comparative outcomes 6.
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • Lobeglitazone
    2013 International Conference on Diabetes and Metabolism Lobeglitazone, A Novel PPAR-γ agonist with balanced efficacy and safety Kim, Sin Gon. MD, PhD. Professor, Division of Endocrinology and Metabolism Department of Internal Medicine, Korea University College of Medicine. Disclosure of Financial Relationships This symposium is sponsored by Chong Kun Dang Pharmaceutical Corp. I have received lecture and consultation fees from Chong Kun Dang. Pros & Cons of PPAR-γ agonist Pros Cons • Good glucose lowering • Adverse effects • Durability (ADOPT) (edema, weight gain, • Insulin sensitizing CHF, fracture or rare effects (especially in MS, macular edema etc) NAFLD, PCOS etc) • Possible safety issues • Prevention of new- (risk of MI? – Rosi or onset diabetes (DREAM, bladder cancer? - Pio) ACT-NOW) • LessSo, hypoglycemiathere is a need to develop PPAR-γ • Few GI troubles agonist• Outcome with data balanced efficacy and safety (PROactive) Insulin Sensitizers : Several Issues Rosi, Peak sale ($3.3 billion) DREAM Dr. Nissen Dr. Nissen ADOPT META analysis BARI-2D (5,8) Rosi, lipid profiles RECORD 1994 1997 1999 2000 2002 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Tro out d/t FDA, All diabetes hepatotoxicity drug CV safety Rosi (5) FDA, Black box Rosi, Rosi , CV safety warning - REMS in USA = no evidence - Europe out Pio (7) PIO, bladder cancer CKD 501 Lobeglitazone 2000.6-2004.6 2004.11-2007.1 2007.3-2008.10 2009.11-2011.04 Discovery& Preclinical study Phase I Phase II Phase III Developmental Strategy Efficacy • PPAR activity Discovery & Preclinical study • In vitro & vivo efficacy • Potent efficacy 2000.06 - 2004.06 Phase I 2004.11 - 2007.01 • In vitro screening • Repeated dose toxicity • Metabolites • Geno toxicity • Phase II CYP 450 • Reproductive toxicity 2007.03 - 2008.10 • DDI • Carcinogenic toxicity ADME Phase III Safety 2009.11 - 2011.04 CV Safety / (Bladder) Cancer / Liver Toxicity / Bone loss Lobeglitazone (Duvie) 1.
    [Show full text]
  • Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes
    Comparative Effectiveness Review Number 14 Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes This report is based on research conducted by the Johns Hopkins Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0018). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services. This report is intended as a reference and not as a substitute for clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. Comparative Effectiveness Review Number 14 Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No.
    [Show full text]
  • Title: Combination of Pparg Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
    Author Manuscript Published OnlineFirst on September 3, 2019; DOI: 10.1158/1078-0432.CCR-19-0976 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas Roberta Frapolli1, Ezia Bello1, Marianna Ponzo1, Ilaria Craparotta2, Laura Mannarino2, Sara Ballabio2, Sergio Marchini2, Laura Carrassa3, Paolo Ubezio4, Luca Porcu5, Silvia Brich6, Roberta Sanfilippo7, Paolo Giovanni Casali7, Alessandro Gronchi8, Silvana Pilotti6, and Maurizio D’Incalci9*. 1 Unit of Preclinical Experimental Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 2 Unit of Translational Genomic, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 3Unit of DNA repair, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 4 Unit of Biophysics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 5 Unit of Methodological Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 6Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 7 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 8 Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 9 Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. Running title: Pioglitazone - trabectedin in myxoid liposarcomas. Keywords: Myxoid liposarcoma, trabectedin resistance, PPAR agonist, and patient-derived xenograft. Additional information: Financial support: This work was supported by the Italian Association for Cancer Research grant to M.D.
    [Show full text]
  • AVANDIA (Rosiglitazone Maleate Tablets), for Oral Use Ischemic Cardiovascular (CV) Events Relative to Placebo, Not Confirmed in Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include all the information needed to use • Fluid retention, which may exacerbate or lead to heart failure, may occur. AVANDIA safely and effectively. See full prescribing information for Combination use with insulin and use in congestive heart failure NYHA AVANDIA. Class I and II may increase risk of other cardiovascular effects. (5.1) • Meta-analysis of 52 mostly short-term trials suggested a potential risk of AVANDIA (rosiglitazone maleate tablets), for oral use ischemic cardiovascular (CV) events relative to placebo, not confirmed in Initial U.S. Approval: 1999 a long-term CV outcome trial versus metformin or sulfonylurea. (5.2) • Dose-related edema (5.3) and weight gain (5.4) may occur. WARNING: CONGESTIVE HEART FAILURE • Measure liver enzymes prior to initiation and periodically thereafter. Do See full prescribing information for complete boxed warning. not initiate therapy in patients with increased baseline liver enzyme levels ● Thiazolidinediones, including rosiglitazone, cause or exacerbate (ALT >2.5X upper limit of normal). Discontinue therapy if ALT levels congestive heart failure in some patients (5.1). After initiation of remain >3X the upper limit of normal or if jaundice is observed. (5.5) AVANDIA, and after dose increases, observe patients carefully for signs • Macular edema has been reported. (5.6) and symptoms of heart failure (including excessive, rapid weight gain; • Increased incidence of bone fracture was observed in long-term trials. dyspnea; and/or edema). If these signs and symptoms develop, the heart (5.7) failure should be managed according to current standards of care.
    [Show full text]
  • The Effect of Rosiglitazone on Overweight Subjects with Type 1 Diabetes
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes SUZANNE M. STROWIG, MSN, RN the potentially serious consequences of PHILIP RASKIN, MD excessive weight gain and insulin- induced hypoglycemia, investigators con- tinue to search for treatments that address both the treatment of insulin deficiency as well as other metabolic abnormalities that OBJECTIVE — To evaluate the safety and effectiveness of rosiglitazone in the treatment of are associated with diabetes (5). overweight subjects with type 1 diabetes. Insulin resistance, a metabolic abnor- mality common in type 2 diabetes, ap- RESEARCH DESIGN AND METHODS — A total of 50 adult type 1 diabetic subjects 2 pears to be present in individuals with with a baseline BMI Ն27 kg/m were randomly assigned in a double-blind fashion to take insulin and placebo (n ϭ 25) or insulin and rosiglitazone 4 mg twice daily (n ϭ 25) for a period of 8 type 1 diabetes, as well. Although insulin months. Insulin regimen and dosage were modified in all subjects to achieve near-normal resistance in type 2 diabetes is generally glycemic control. associated with obesity, hypertension, dyslipidemia, and other metabolic disor- RESULTS — Both groups experienced a significant reduction in HbA1c (A1C) level (rosigli- ders, studies have shown that overweight tazone: 7.9 Ϯ 1.3 to 6.9 Ϯ 0.7%, P Ͻ 0.0001; placebo: 7.7 Ϯ 0.8 to 7.0 Ϯ 0.9%, P ϭ 0.002) and as well as normal-weight adults with type a significant increase in weight (rosiglitazone: 97.2 Ϯ 11.8 to 100.6 Ϯ 16.0 kg, P ϭ 0.008; 1 diabetes can have peripheral and he- Ϯ Ϯ ϭ ϭ placebo: 96.4 12.2 to 99.1 15.0, P 0.016).
    [Show full text]